Featured Research

from universities, journals, and other organizations

Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma

Date:
December 10, 2002
Source:
Dana-Farber Cancer Institute
Summary:
A drug similar to thalidomide has been found to be promising with fewer side effects for treating patients with recurrent multiple myeloma, an incurable form of bone marrow cancer, according to early data from a clinical study led by Dana-Farber Cancer Institute researchers.

PHILADELPHIA -- A drug similar to thalidomide has been found to be promising with fewer side effects for treating patients with recurrent multiple myeloma, an incurable form of bone marrow cancer, according to early data from a clinical study led by Dana-Farber Cancer Institute researchers.

Paul Richardson, MD, Kenneth Anderson, MD, both of Dana-Farber, and their co-authors will present preliminary safety and effectiveness data from a large multi-center Phase II study of CC-5013 at the annual meeting of the American Society of Hematologists in Philadelphia (Dec. 9, 10:45 a.m., Room 103). Celgene Corporation manufactures CC-5013, which is also known as Revimid TM.

The drug, an analog of thalidomide, was developed to be more potent than thalidomide, while reducing some of thalidomide's dose limiting side effects. Laboratory studies led by Teru Hideshima, MD, at Dana-Farber have shown that CC-5013 not only kills myeloma cells by triggering their innate self-destruct mechanism but also inhibits the myeloma cells ability to localize and grow in the bone marrow. Moreover, it appears to have anti-angiogenic effects and stimulates the immune system to attack myeloma.

"We are encouraged by the responses seen so far, and the relative tolerability of this convenient orally active agent is a real plus for patients," says Richardson.

A Phase I study led by the same Dana-Farber investigators determined a maximum tolerated dose of the drug. The new study, which began earlier this year, compared two therapeutic regimens: one in which patients took 15 mg. of the drug twice daily for three weeks followed by a week of rest, and one in which patients followed the same schedule but with 30 mg. as a once daily dose. Dexamethasone could be added in patients in whom CC-5013 alone was not proving beneficial as laboratory studies have suggested that the two agents combined have at least additive activity in myeloma.

Preliminary results from the trial show that there is significant anti-myeloma activity with measurable responses in about 50 percent of evaluable patients treated to date. The drug has been well tolerated, with evidence that the daily dosing regimen has fewer side effects than the twice daily schedule, but equal activity.

Dana-Farber Cancer Institute (http://www.danafarber.org) is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute.


Story Source:

The above story is based on materials provided by Dana-Farber Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Dana-Farber Cancer Institute. "Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma." ScienceDaily. ScienceDaily, 10 December 2002. <www.sciencedaily.com/releases/2002/12/021210074407.htm>.
Dana-Farber Cancer Institute. (2002, December 10). Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma. ScienceDaily. Retrieved July 29, 2014 from www.sciencedaily.com/releases/2002/12/021210074407.htm
Dana-Farber Cancer Institute. "Thalidomide-Like Compound Shows Early Promise Against Multiple Myeloma." ScienceDaily. www.sciencedaily.com/releases/2002/12/021210074407.htm (accessed July 29, 2014).

Share This




More Health & Medicine News

Tuesday, July 29, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Deadly Ebola Virus Threatens West Africa

Deadly Ebola Virus Threatens West Africa

AP (July 28, 2014) West African nations and international health organizations are working to contain the largest Ebola outbreak in history. It's one of the deadliest diseases known to man, but the CDC says it's unlikely to spread in the U.S. (July 28) Video provided by AP
Powered by NewsLook.com
$15B Deal on Vets' Health Care Reached

$15B Deal on Vets' Health Care Reached

AP (July 28, 2014) A bipartisan deal to improve veterans health care would authorize at least $15 billion in emergency spending to fix a veterans program scandalized by long patient wait times and falsified records. (July 28) Video provided by AP
Powered by NewsLook.com
Two Americans Contract Ebola in Liberia

Two Americans Contract Ebola in Liberia

Reuters - US Online Video (July 28, 2014) Two American aid workers in Liberia test positive for Ebola while working to combat the deadliest outbreak of the virus ever. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins